Given the multifaceted nature of ADCs, developers should have an integrated analytical toolkit. Three complementary approaches dominate the current landscape: Ligand Binding Assays (LBA): Ideal for ...

Over the last several decades, mounting interest has positioned bioconjugate therapeutics as one of the most promising biopharmaceutical modalities. Work in chemical biology, including novel ...

Antibody-Drug Conjugates (ADCs) are an exciting new class of drugs that offers clinical benefits to a wide range of cancers. Unlike immune modulating monoclonal antibodies (mAbs) such as checkpoint ...

The precise delivery of the payload relies on the specificity of the mAb and the unique presentation of the selected epitope. Ideally, the chosen epitope is present exclusively and abundantly on ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza's commitment to helping customers deliver ...

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform -- Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ...

This novel approach utilizes cysteine-engineered antibodies which allows for the development of uniform and homogenous ADCs with precise control of the drug to antibody ratio (DAR). The drug-payload, ...

As a leading CRO, Creative Biolabs employs AI-driven chemical synthesis to integrate smart algorithms with experimental chemistry and accelerate drug discovery ...